Grant: CIHR Fellowship
Direct Payment
$60,000.00
The potential of new MRI biomarkers to increase accuracy and cost-effectiveness in osteoarthritis research and care: analysis of longitudinal data from the Osteoarthritis Initiative
EF 2012-13
Résumé
Imagine if the trigger for treating heart disease were a heart attack, for treating high blood pressure, a stroke, or for osteoporosis, a fracture. Fortunately, tests exist (e.g., cholesterol, blood pressure, bone density x-ray) that detect disease before symptoms appear, so the devastating outcomes can be prevented. Unfortunately, the same approach doesn't apply to osteoarthritis (OA), the most common arthritis worldwide and leading cause of disability in Canada. The prevalence of OA is projected to double by 2020, due to increases in obesity, sports trauma and longevity.
Detecting OA early is key. Currently x-ray is the most widely used test but is not strongly linked with pain and doesn't show early OA - a critical period for treatment. Conversely MRI is related to pain and shows early disease, but is expensive due to the time to interpret images, and is largely subjective. This has resulted in small research samples with limited power to show important changes, and a sometimes confusing array of information for physicians.
New MRI software has been developed and pilot-tested that provides readings that are semi-automated (rapid) and objective, leading to faster, cheaper, and more accurate diagnosis. However they have not been fully tested in large datasets - a necessary step before widespread research and clinical use.
This research will compare new MRI measures to conventional MRI, testing them for the ability to correlate with a patient's pain and function, identify early disease and progression, and reduce reading times.
Significance: This work will immediately benefit researchers with improved and earlier diagnosis at lower costs leading to larger, more powerful studies. This will strengthen prevention efforts and lead to earlier interventions to prevent disability. It will benefit physicians through development of a single diagnostic score for knee OA (similar to the bone density score for osteoporosis) leading to earlier and better treatment.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
282523
Name
Ratzlaff Charles R
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Allied Health Professionals - Fellowships
Projecttitle
The potential of new MRI biomarkers to increase accuracy and cost-effectiveness in osteoarthritis research and care: analysis of longitudinal data from the Osteoarthritis Initiative
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Epidemiology; Hip; Imaging; Knee; Magnetic Resonance Imaging; Osteoarthritis; Outcome Measurement
Abstract
Imagine if the trigger for treating heart disease were a heart attack, for treating high blood pressure, a stroke, or for osteoporosis, a fracture. Fortunately, tests exist (e.g., cholesterol, blood pressure, bone density x-ray) that detect disease before symptoms appear, so the devastating outcomes can be prevented. Unfortunately, the same approach doesn't apply to osteoarthritis (OA), the most common arthritis worldwide and leading cause of disability in Canada. The prevalence of OA is projected to double by 2020, due to increases in obesity, sports trauma and longevity.
Detecting OA early is key. Currently x-ray is the most widely used test but is not strongly linked with pain and doesn't show early OA - a critical period for treatment. Conversely MRI is related to pain and shows early disease, but is expensive due to the time to interpret images, and is largely subjective. This has resulted in small research samples with limited power to show important changes, and a sometimes confusing array of information for physicians.
New MRI software has been developed and pilot-tested that provides readings that are semi-automated (rapid) and objective, leading to faster, cheaper, and more accurate diagnosis. However they have not been fully tested in large datasets - a necessary step before widespread research and clinical use.
This research will compare new MRI measures to conventional MRI, testing them for the ability to correlate with a patient's pain and function, identify early disease and progression, and reduce reading times.
Significance: This work will immediately benefit researchers with improved and earlier diagnosis at lower costs leading to larger, more powerful studies. This will strengthen prevention efforts and lead to earlier interventions to prevent disability. It will benefit physicians through development of a single diagnostic score for knee OA (similar to the bone density score for osteoporosis) leading to earlier and better treatment.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ratzlaff, Charles R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~